We labeled lgG with phospholipase C, using 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimide. Enzymatic activity of the resulting conjugate was inhibited when it was complexed with human lg(, but rabbit or goat lgG was not effective in suppressing the enzyme activity. Normal erythrocytes were used as substrate for the enzyme, enzymatic activity being assessed by measuring the release Qf hemoglobin. The substrates for phospholipase C are phospholipids, which are major components of the erythrocyte membranes. Hence, the phospholipids in the membranes are viewed as being "immObilized." Perhaps such immobilization of substrate may be a requisite to the inhibition phenomenon.
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Phospholipase
C (EC 3.1.4.3) is produced by a number of Gram-positive bacilli, e.g., Clostridium welchii.
It acts on such phospholipids as phosphatidyl choline, phosphatidyl ethanolamine, and sphingomyelin, and catalyzes hydrolysis of the ester bond between glycerol and phosphate as shown in the adjacent column.
These phospholipids are major lipid components of erythrocyte membranes. Hydrolysis of the phospholipids results in a loss of integrity of the membrane and release of cellular contents. Hemolytic action of phospholipase C was described as early as 1947 by Miles and Miles (1) . Subsequently a number of investigators, including Macfarlane (2) , reported detailed studies on the hemolysis of erythrocytes.
Whether the enzyme has similar lytic effect on other types of mammalian cells has not been reported. Erythrocytes are ideal for the present investigation, because they are conveniently obtainable, they contain a natural marker (hemoglobin), and serve as an "immobilized" substrate. activity of the resulting conjugate was suppressed by IgG. Here, we report and discuss our observations of this inhibition phenomenon.
Materials and Methods

Materials
Human, goat, and rabbit IgG were purified from the respective normal sera by ammonium sulfate precipitation followed by chromatography on diethylaminoethyl-cellulose (3) . Antihuman IgG was obtained by immunizing rabbits by repeated injections of purified human IgG mixed with Freund's adjuvant. Antihuman IgG was purified by using human IgG coupled to CNBr-activated agarose (4) . Phospholipase C (6 kU/g) was obtained from Sigma Chemical Co., St. Louis, To 13 mg of phospholipase C dissolved in 1.0 ml of phosphate-buffered saline (sodium phosphate buffer, 10 mmol/liter, pH 6.0; NaCl, 150 mmol/liter) add 16 mg of 1-cyclohexyl-3-(2-morpholinethyl)-carbodiimide. Maintain the pH near 6.0 during the first hour of incubation. Stir the mixture overnight at 4 #{176}C. After overnight dialysis against three changes, 1 liter each, of phosphate-buffered saline (sodium phosphate buffer, 10 mmol/liter, pH 7.2; NaC1, 150 mmol/liter) add 5.0 mg of anti-IgG. Adjust the pH to about 9.0 and stir for 48 h. Dialyze the mixture against 1 liter of phosphatebuffered saline (pH 7.2) and chromatograph 0.5 ml of the mixture on a 1 X 30 cm column of Sepharose 6B (Pharmacia Fine Chemicals Inc., Piscataway, N. J. 08854). Pool the fractions that contain the major protein that first emerges from the column and dilute as appropriate in phosphate-buffered saline (pH 7.2) containing highly purified bovine serum albumin (Calbiochem, La Jolla, Calif. 92037). Use this preparation as the source of the enzyme-labeled antihuman IgG.
Assay for inhibition of phospholipase C activity by
human IgG. Packed erythrocytes were diluted 30-fold in phosphate-buffered saline (pH 7.2). Incubate 50 l of the enzyme-labeled antihuman IgG with various quantities of IgG (50 gil) for 30 mm at 37 #{176}C. Next add 0.5 ml of the diluted cell suspension and incubate for as long as 30 mm at 37 #{176}C, with occasional mixing, then centrifuge to sediment the intact cells. Carefully remove the supernate, mix it with 0.7 to 1.5 ml of cyanomethemoglobin reagent (Hycel Inc., Houston, Tex.), and measure the absorbance at 540 nm. Use a mixture of 0.7-1.5 ml of cyanomethemoglobin reagent and 0.5 ml of incubation mixture that does not contain the enzyme-labeled antihuman IgG as a blank for zero calibration of the spectrophotometer.
Results
The inhibitory effect of IgG on the enzyme activity of the enzyme-antihuman IgG conjugate can be demonstrated by use of several variables, including the concentrations of IgG or the labeled anti-IgG, or the time required for equilibrium to be reached between the ligands. At an IgG concentration of 2.2 g/liter or greater, erythrocyte lysis was almost completely inhibited. Binding the IgG to the labeled anti-IgG was maximum within 30 mm of incubation. Figure 1 shows the relation between hemoglobin release and time in the presence of different quantities of IgG. As the amount of IgG present was decreased, erythrocyte lysis increased, indicating an inverse relationship between the concentration of IgG and enzyme activity. We also examined and compared the effect of goat and rabbit IgG with that of human IgG (Figure 2) . At the concentration indicated, neither was inhibitory, presumably because the immunoglobulin was not complexing with the labeled antihuman IgG. Although not shown here, the inhibisl*strate ti-I Fig. 3 . Suggested mechanism of inhibition of enzyme activity by lgG.
tory effect of IgG was demonstrable in the microgram range.
Discussion
The effect of IgG described here may be explained by the hypothetical scheme shown in Figure 3 . When IgG complexes with the enzyme-anti-IgG conjugate, the catalytic site of the enzyme is "masked" by IgG, preventing its interaction with the substrate. Such an inhibitory effect of IgG is probably made possible because the substrate is an integral part of a large membraneous structure and may be viewed as being immobilized, and therefore becomes less accessible to the catalytic site of the enzyme. Appropriate attachment of substrate to other solid matrices may similarly be effective for inhibiting enzyme activity of labeled antibody in the bound state. This type of approach would simplify analytical procedures for monitoring immunological reactions as compared to those that necessitate phase separation.
